St. Jude Medical says it is seeking European regulatory permission to sell a device that somewhat alleviates migraine headaches. Yes, "somewhat" as initial testing has fallen short of the FDA's overall goals, but even so, a quarter of the group experienced a decrease in headaches. The future of the device in the U.S. market remains unclear, because in tests the experimental, implantable device didn't reduce pain levels by the amount required by the U.S. Food and Drug Administration (FDA.) St. Jude, based in Little Canada, said that a study of 157 patients with serious recurring migraine headaches found that, among those treated, there was about a 27% decrease in headaches. However, patients in the study didn't meet the FDA's requirement of a 50% reduction in pain from migraines. Patients in the study were asked to define their headache relief as excellent, good, fair, uncertain, or poor.
Headaches can take a serious toll on a child's quality of life by limiting participation in social events, play, sports and school-related activities. Between 4 to 10 percent of children suffer from migraines headaches each year, according to the American Headache Society. "Headaches in children are a fairly common problem and physicians continue to see and treat a steady stream of children with them, " said pediatric neurologist Dr. Eugene Schnitzler of Loyola University Medical Center in Maywood, Ill. Fortunately, in most cases the causes of childhood headaches are usually no cause for alarm, Schnitzler said. Children can get headaches from stress, anxiety, inadequate sleep, vision problems, caffeine or food sensitivities. To help pinpoint the cause, Loyola has opened a clinic that's exclusively devoted to treating children with headaches.
Surgery to "deactivate" migraine headaches produces lasting good results, with nearly 90 percent of patients having at least partial relief at five years' follow-up, reports a study in the February issue of Plastic and Reconstructive Surgery® , the official medical journal of the American Society of Plastic Surgeons (ASPS). In about 30 percent of patients, migraine headaches were completely eliminated after surgery, according to the new study, led by Dr. Bahman Guyuron of Case Western Reserve University and the Cleveland Clinic. 'Trigger Site' Surgery Reduces or Eliminates Migraine Headaches Dr. Guyuron, a plastic surgeon, developed the migraine surgery techniques after noticing that some migraine patients had reduced headache activity after undergoing cosmetic forehead-lift procedures.
The popular anti-wrinkle jab, Botox, is unlikely to offer much benefit in its most recently licensed use - as a treatment for chronic migraine - says the new look Drug and Therapeutics Bulletin (DTB). Botulinum toxin is a neurotoxin derived from the bacterium Clostridium botulinum. It is used as a treatment for various conditions involving muscle spasm and is available in several formulations. These include Botox (a form of botulinum toxin A), which is widely used, though not actually licensed, for the smoothing out of facial wrinkles. Botox has now been licensed for use to relieve the symptoms of chronic migraine as a series of regular injections into up to 39 sites in the head and neck muscles. How it is supposed to work in chronic migraine has not been clearly established, but this action appears distinct from Botox's well known paralysing effect on muscles.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, has announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide. Presented at the 15th International Headache Congress in Berlin, Germany, the study shows statistically significant improvement across multiple measures including a reduction in the number of headache days per month and improvement in quality of life. This is the largest clinical study to date evaluating the use of PNS via an implanted medical device for the treatment of chronic migraine. The study followed 157 participants who, on average, suffered from headache 26 days per month.